About The Study: A proposed U.S. Drug Enforcement Administration rule could impede buprenorphine initiation for a substantial number of patients with opioid use disorder. In this study, more than 4,500 tele-buprenorphine initiations from 2020 to 2022—20% of tele-initiations overall—would have been prohibited under requirements for an in-person visit with the tele-initiating clinician prior to or within 30 days after tele-initiation.
Corresponding Author: To contact the corresponding author, Emma E. McGinty, PhD, email emm4010@med.cornell.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.0001)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2025.0001?guestAccessKey=c0957767-f5eb-4d6d-88a4-15c747418b57&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=030325
About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.
JAMA Network Open